Covance recognized for providing superior vaccine services to biopharmaceutical industry.
Princeton, NJ-May 5, 2008-Covance (www.covance.com), the world’s largest publicly traded contract research organization, today announced that it has won the “Best Contract Research Organization (CRO)” award at the 2008 World Vaccine Congress, held recently in Washington, DC. As part of the Vaccine Industry Excellence (ViE) awards, the Best CRO award is designed to highlight the importance of contract research services within the vaccine industry. This award recognizes Covance as best-in-class when it comes to providing services that support vaccine development.
“This recognition reaffirms our commitment to providing vaccine services that encompass all phases of development,” said Wendel Barr, chief operating officer for Covance. “We understand that each vaccine is unique, and therefore we offer services and experience-including scientific, technical, and regulatory expertise-across different types of vaccines to help guide our customers through the complexities of vaccine development.”
A panel of international judges selected Covance based on the company’s state-of-the-art facilities, vaccine services, and superior customer relations that together help biopharmaceutical companies speed vaccine development. The ViE Awards were created to honor and generate public recognition of the efforts, accomplishments, and positive contributions of organizations and individuals in the global vaccine industry.
The global vaccine market generated sales of $13.5 billion in 2006 and is expected to reach $24.8 billion by 2013, according to a 2007 report published by Wood Mackenzie, a research and consulting firm.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.